药物诱导的脱发区域来自Upadacitinib
Alexander H Chang1, Nicholas D Brownstone1, Sylvia Hsu1
1Dermatology, Temple University Hospital, Philadelphia, USA.
Cureus
|September 11, 2024
概括
一名妇女在一年内治疗阿托皮性皮肤炎的阿帕达西替尼 (upadacitinib) 后出现了白发症 (alopecia areata,AA). 这种情况表明,upadacitinib可能会导致AA,一种潜在的药物诱导脱发症,以前没有记录过.
科学领域:
- 皮肤病学 皮肤病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 亚托皮炎是一种慢性炎症性皮肤疾病.
- 乌帕达西替尼 (Upadacitinib) 是一种简氏激酶 (JAK) 抑制剂,用于治疗中度至重度的亚托邦性皮炎.
研究的目的:
- 报告一种可能由upadacitinib诱导的新发性白发症病例.
- 讨论这一发现对药物安全和患者监测的影响.
主要方法:
- 一个55岁的女性患者的病例报告,患有亚托邦性皮炎.
- 在上达西替尼治疗期间观察不良事件.
主要成果:
- 患者在启动上达西提尼布治疗后大约一年内出现了大发性脱发症.
- 这代表了upadacitinib治疗的潜在新副作用.
结论:
- 乌帕达西提尼布可能与白发病的发展有关.
- 需要进一步的研究来确认upadacitinib和AA之间的因果关系.
- 这一案例凸显了JAK抑制剂治疗期间监测意外皮肤学副作用的重要性.
相关概念视频
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
154
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
154
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
145
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
145
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
98
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
98


